2024-03-28T23:33:24Z
http://repoint.unil.ch/oaiprovider/
oai:serval.unil.ch:BIB_9646C9E25D4B
2024-03-23T02:43:01Z
serval:BIB_9646C9E25D4B
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
10.1200/JCO.21.00276
000708109700004
34251873
Rothschild
S.I.
author
Zippelius
A.
author
Eboulet
E.I.
author
Savic Prince
S.
author
Betticher
D.
author
Bettini
A.
author
Früh
M.
author
Joerger
M.
author
Lardinois
D.
author
Gelpke
H.
author
Mauti
L.A.
author
Britschgi
C.
author
Weder
W.
author
Peters
S.
author
Mark
M.
author
Cathomas
R.
author
Ochsenbein
A.F.
author
Janthur
W.D.
author
Waibel
C.
author
Mach
N.
author
Froesch
P.
author
Buess
M.
author
Bohanes
P.
author
Godar
G.
author
Rusterholz
C.
author
Gonzalez
M.
author
Pless
M.
author
Swiss Group for Clinical Cancer Research (SAKK)
contributor
article
2021-09-10
Journal of clinical oncology
1527-7755
0732-183X
journal
39
26
2872-2880
eng
60_published
peer-reviewed
Publication types: Journal Article
Publication Status: ppublish